Stock Performance - Oscar Health Inc ended the recent trading session at $16 28, showing a -0 12% change from the previous day's closing price [1] - The stock underperformed compared to the S&P 500 (0 92% gain), Dow (0 31% gain), and Nasdaq (2 03% gain) on the same day [1] - Over the past month, the company's shares gained 20 03%, outperforming the Finance sector (4 35% gain) and the S&P 500 (0 81% gain) [1] Earnings and Revenue Expectations - The company's upcoming earnings report is scheduled for February 4, 2025 [2] - Analysts expect Oscar Health Inc to post earnings of -$0 58 per share, representing a 12 12% year-over-year growth [2] - Revenue is projected to be $2 46 billion, indicating a 71 91% increase compared to the same quarter of the previous year [2] Analyst Estimates and Stock Performance - Recent changes in analyst estimates often reflect shifts in near-term business trends [3] - Positive revisions in estimates typically indicate analysts' confidence in the company's business performance and profit potential [3] - Adjustments in estimates are directly associated with imminent stock price performance [4] Valuation Metrics - Oscar Health Inc has a Forward P/E ratio of 21 31, which is higher than its industry's Forward P/E of 9 98 [6] - The company's PEG ratio is 0 65, lower than the industry average of 1 09 for Insurance - Multi line stocks [6] Industry Ranking - The Insurance - Multi line industry is part of the Finance sector and has a Zacks Industry Rank of 89, placing it in the top 36% of all industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7] Zacks Rank System - Oscar Health Inc currently has a Zacks Rank of 3 (Hold) [5] - The Zacks Rank system, ranging from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 ranked stocks delivering an average annual return of +25% since 1988 [5]

Market Performance - Oscar Health, Inc (OSCR) closed at $15 65, with a -1 57% movement compared to the previous day, lagging behind the S&P 500's 0 88% gain, the Dow's 1 24% gain, and the Nasdaq's 0 65% gain [1] - Over the past month, OSCR shares gained 16 91%, outperforming the Finance sector's 3 25% gain and the S&P 500's 1 17% gain [1] Earnings and Revenue Expectations - The company is expected to report earnings on February 4, 2025, with an EPS of -$0 58, up 12 12% from the prior-year quarter [2] - Revenue is expected to be $2 46 billion, a 71 91% increase compared to the year-ago quarter [2] Analyst Estimates and Revisions - Recent adjustments to analyst estimates reflect shifting short-term business dynamics, with positive revisions indicating optimism about the company's business and profitability [3] - Estimate revisions are directly related to near-term stock moves, and the Zacks Rank model considers these changes to provide actionable ratings [4] Valuation Metrics - OSCR currently has a Forward P/E ratio of 20 78, indicating a premium compared to its industry's Forward P/E of 9 74 [6] - The company's PEG ratio is 0 64, lower than the Insurance - Multi line industry average of 1 05, suggesting potential undervaluation relative to earnings growth [7] Industry Ranking - The Insurance - Multi line industry, part of the Finance sector, has a Zacks Industry Rank of 142, placing it in the bottom 44% of all industries [7] - The top 50% of industries outperform the bottom half by a factor of 2 to 1, based on the Zacks Industry Rank [8]

Earnings and Revenue Estimates - Full-year Zacks Consensus Estimates for Oscar Health, Inc predict earnings of -$0 01 per share and revenue of $9 25 billion, representing year-over-year changes of +99 18% and +57 71% respectively [1] - The upcoming earnings release is expected to show earnings of -$0 58 per share, marking a year-over-year growth of 12 12%, with revenue estimated at $2 46 billion, a 71 91% increase compared to the year-ago quarter [6] Stock Performance - Oscar Health, Inc closed at $13 58 in the latest trading session, marking a -1 59% move from the previous day, lagging behind the S&P 500's daily loss of 1 07%, the Dow's loss of 0 97%, and the Nasdaq's loss of 1 19% [5] - Prior to today's trading, the company's shares had lost 20 37% over the past month, underperforming the Finance sector's loss of 4 94% and the S&P 500's loss of 0 36% [10] Industry and Sector Analysis - The Insurance - Multi line industry, part of the Finance sector, currently has a Zacks Industry Rank of 69, placing it in the top 28% of all 250+ industries [3] - The Zacks Industry Rank measures the strength of individual industry groups, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [9] Analyst Estimates and Zacks Rank - Recent modifications to analyst estimates for Oscar Health, Inc often reflect short-term business patterns, with upbeat changes indicating a favorable outlook on the company's business health and profitability [7] - The Zacks Rank system, ranging from 1 (Strong Buy) to 5 (Strong Sell), has a notable track record of outperformance, with 1 rated stocks producing an average annual return of +25% since 1988 Oscar Health, Inc currently holds a Zacks Rank of 3 (Hold) [8]

Investors might want to bet on Oscar Health, Inc. (OSCR) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.T ...

Earnings Call Overview - Oscar Health Inc held its Q3 2024 earnings conference call on November 7, 2024, at 8:00 AM ET [1] - The call was hosted by CEO Mark Bertolini and CFO Scott Blackley, with Chris Potochar, VP of Treasury and IR, facilitating the introduction [3] - Participants included analysts from Wells Fargo, Raymond James, Piper Sandler, Nephron Research, Baird, and Bank of America [1] Access to Earnings Information - The earnings call was accessible through the company's Investor Relations website at ir hioscar com [3] - Full details of the results and additional management commentary were available in the earnings release on the same website [3] Forward-Looking Statements - Remarks made during the call about the future were classified as forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 [4] - Actual results may differ materially from these forward-looking statements due to various important factors discussed in the company's quarterly report on Form 10-Q for the period ended June 30, 2024, and other filings [4]

Start Time: 08:00 January 1, 0000 8:36 AM ET Oscar Health, Inc. (NYSE:OSCR) Q3 2024 Earnings Call November 07, 2024, 08:00 AM ET Company Participants Mark Bertolini - CEO Scott Blackley - Chief Financial Officer Chris Potochar - VP, Treasury and IR Conference Call Participants Stephen Baxter - Wells Fargo John Ransom - Raymond James Jessica Tassan - Piper Sandler Joshua Raskin - Nephron Research Michael Ha - Baird Adam Ron - Bank of America Operator Good morning. My name is Angela, and I will be your confer ...

Membership and Growth - As of September 30, 2024, Oscar Health, Inc. has approximately 1.65 million members, reflecting the company's member-first philosophy and innovative approach to care[93] - Membership increased by 671,124, or 68%, as of September 30, 2024, compared to September 30, 2023, driven by strong retention and new enrollments[117] - The company expects transitions from Medicaid and CHIP coverage to ACA marketplace plans to contribute to growth in the ACA marketplace[110] Financial Performance - Total revenue for the three months ended September 30, 2024, was $2,423.5 million, up from $1,440.0 million in the same period of 2023, representing a 68.3% increase[1] - Premium revenue increased by $976.2 million, or 70%, for the three months ended September 30, 2024, compared to the same period in 2023[118] - Medical expenses increased by $840.8 million, or 72%, for the three months ended September 30, 2024, compared to the same period in 2023[121] - Adjusted EBITDA for the nine months ended September 30, 2024, was $311.9 million, compared to $66.4 million for the same period in 2023[127] - Selling, general, and administrative expenses increased by $134.5 million, or 41%, for the three months ended September 30, 2024, compared to the same period in 2023[123] - Investment income increased by $8.0 million, or 19%, for the three months ended September 30, 2024, compared to the same period in 2023[119] Medical Loss Ratio and Expenses - The medical loss ratio (MLR) is a key metric indicating the ratio of medical expenses to net premiums, which is subject to federal and state minimum requirements[97] - Medical Loss Ratio (MLR) was 84.6% for the three months ended September 30, 2024, compared to 83.8% for the same period in 2023[122] - Medical expenses are influenced by seasonal patterns, with higher costs typically occurring in the second half of the year due to various factors[107] Capital and Cash Flow - The combined statutory capital and surplus of health insurance subsidiaries was $1,068.0 million as of September 30, 2024, exceeding minimum capital requirements[132] - Health insurance subsidiaries issued dividends and made loan repayments of $133 million to the Parent during the nine months ended September 30, 2024[133] - For the nine months ended September 30, 2024, the company made capital contributions of $99.8 million to its health insurance subsidiaries, compared to $16.5 million for the same period in 2023[134] - Net cash provided by operating activities for the nine months ended September 30, 2024, was $631.4 million, an increase from a net cash outflow of $569.0 million for the same period in 2023[146] - Net cash used in investing activities for the nine months ended September 30, 2024, was $1,356.0 million, compared to net cash provided of $404.7 million for the same period in 2023[147] - Net cash provided by financing activities for the nine months ended September 30, 2024, was $64.6 million, up from $5.4 million for the same period in 2023, primarily due to proceeds from stock option exercises[148] Regulatory and Operational Developments - The company has announced it will not renew the Cigna+Oscar Small Group arrangement, effective December 31, 2024, and will exit the small group market entirely by December 15, 2024[112] - Oscar Health is monitoring regulatory developments, including changes to the ACA broker process to address unauthorized enrollment changes[111] - A cybersecurity incident involving Change Healthcare occurred on February 21, 2024, but no breach of member data has been reported[113] Investment and Financial Strategy - The company estimates that without quota share reinsurance arrangements, its health insurance subsidiaries would have needed to hold approximately $520.0 million and $447.1 million of additional capital as of September 30, 2024, and December 31, 2023, respectively[134] - The fair value of the company's investments would decrease by approximately $44.1 million with a hypothetical and immediate 1% increase in interest rates as of September 30, 2024[150] - The company has $115.0 million available to draw under its Revolving Credit Facility until December 2025, with no outstanding borrowings as of September 30, 2024[141] - The company expects cash flows from operations to primarily fund its long-term cash requirements under various contractual obligations[138] - The company’s investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, consistent with state requirements[144]

Oscar Health, Inc. (OSCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.20, delivering a surprise of 25%.Over the last four quarters, the company has surpas ...

Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Announces Results for Third Quarter 2024 November 7, 2024 • For the quarter ended September 30, 2024: ◦ Total Revenue of $2.4 billion, a 68% increase year-over-year ◦ Medical Loss Ratio of 84.6%, an 80 bps increase year-over-year ◦ SG&A Expense Ratio of 19.0%, a 360 bps improvement year-over-year ◦ Net loss attributable to Oscar of $54.6 million, or $(0.22) of earnings per share, a $10.8 million improvement yearover-year ◦ Adjusted EBITDA loss of $ ...

Oscar Health reported a $54 million third quarter 2024 loss despite continued growth, heading into ... [+] what could be an uncertain political period under Donald Trump and Republicans in Congress. Oscar Health photo Oscar Health Thursday reported a $54 million third quarter loss despite continued growth, heading into what could be an uncertain political period under Donald Trump and Republicans in Congress. But those running the provider of individual coverage under the Affordable Care Act ssay they belie ...